Dmk Pharmaceuticals CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
DMK Pharmaceuticals has sold its ZIMHI assets for $3.17 million and announced the resignation of its board and CEO, effective June 27, 2024, following its Chapter 11 bankruptcy filing.
DMK Pharmaceuticals Corporation received notice of its impending delisting from the Nasdaq Capital Market following a trading suspension.
DMK Pharmaceuticals has filed for Chapter 11 bankruptcy and anticipates its stock will be delisted from the Nasdaq.
8-K: DMK Pharmaceuticals Holds Reconvened Annual Meeting, Elects Directors and Approves Key Proposals
DMK Pharmaceuticals successfully held its reconvened annual meeting, electing five directors, approving amendments to its equity incentive plan, and ratifying its auditor.
DMK Pharmaceuticals Corporation has amended its bylaws to change the quorum requirements for stockholder meetings, effective January 22, 2024.